Thrombotic Events during Lenvatinib Treatment: A Single Institution Experience

Lenvatinib is the standard treatment for radioiodine-refractory differentiated thyroid cancer (RR-DTC). Thromboembolic (TE) side effects are quite rare (1–3% of treated patients) in clinical trials. Nevertheless, patients with predisposing factors are at a higher risk of developing cardiovascular ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Denaro, Nerina, Garrone, Ornella, Ghidini, Michele, Tomasello, Gianluca, Hahne, Jens Claus, Merlano, Marco Carlo, Locati, Laura Deborah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785927/
https://www.ncbi.nlm.nih.gov/pubmed/36555928
http://dx.doi.org/10.3390/jcm11247312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785927/
https://www.ncbi.nlm.nih.gov/pubmed/36555928
http://dx.doi.org/10.3390/jcm11247312

Ejemplares similares